Shivv
@shivv
@shivv
Retail Clinics Market Will Gain Considerably from Rising Cases of Communicable Diseases, says Fortune Business Insights
Market Overview
Rising prevalence of communicable diseases around the world is driving the global retail clinics market, says Fortune Business Insights in a report, titled “Retail Clinics Market Size, Share and Global Trend by Location (Departmental Stores, Shopping Malls, Retail Stores, Others) By Ownership (Standalone, Hospital-owned, Investor-owned, Others), By Mode of Payment (Insurance, Out-of-Pocket) and Geography Forecast till 2026.”Improved accessibility of healthcare for the geriatric population is a key factor predicted to contribute significantly to the global retail clinics market.
Market Overview
Rising prevalence of communicable diseases around the world is driving the global retail clinics market, says Fortune Business Insights in a report, titled “Retail Clinics Market Size, Share and Global Trend by Location (Departmental Stores, Shopping Malls, Retail Stores, Others) By Ownership (Standalone, Hospital-owned, Investor-owned, Others), By Mode of Payment (Insurance, Out-of-Pocket) and Geography Forecast till 2026.”Improved accessibility of healthcare for the geriatric population is a key factor predicted to contribute significantly to the global retail clinics market.
Global Capsule Endoscopy Market Likely to Witness Growth Due to Increasing Cases of Cancer and Gastrointestinal Diseases Reported Worldwide, says Fortune Business Insights
Market Overview
The global “capsule endoscopy market” is likely to derive growth from the rise in the number of chronic diseases, namely, cancer and gastrointestinal diseases across the globe. Fortune Business Insights, in a report, titled “Capsule Endoscopy Market Size, Share And Global Trend By Product (Oesophageal Capsule, Small Bowel Capsule,Colon Capsule), By Application (Obscure Gastrointestinal Bleeding, Crohn’s Disease, Small Intestine Tumor), By End User (Hospitals, Diagnostic Laboratories, Specialty Clinics), And Geography Forecast Till 2026,” states that there has been advancements in hybrid imaging techniques as well as capsule endoscopy technology, which in turn is propelling the global endoscopy market. Also, patients have recently started favoring advanced and modern diagnostics for fast recovery. This is one of the most significant factors that has been contributing towards the growth of the global capsule endoscopy market. The report classifies the global endoscopy market in terms of four segments, namely, by product, by application, by end user, and by geography. By product, the market is divided into esophageal capsule, small bowel capsule, and colon capsule.
Market Overview
The global “capsule endoscopy market” is likely to derive growth from the rise in the number of chronic diseases, namely, cancer and gastrointestinal diseases across the globe. Fortune Business Insights, in a report, titled “Capsule Endoscopy Market Size, Share And Global Trend By Product (Oesophageal Capsule, Small Bowel Capsule,Colon Capsule), By Application (Obscure Gastrointestinal Bleeding, Crohn’s Disease, Small Intestine Tumor), By End User (Hospitals, Diagnostic Laboratories, Specialty Clinics), And Geography Forecast Till 2026,” states that there has been advancements in hybrid imaging techniques as well as capsule endoscopy technology, which in turn is propelling the global endoscopy market. Also, patients have recently started favoring advanced and modern diagnostics for fast recovery. This is one of the most significant factors that has been contributing towards the growth of the global capsule endoscopy market. The report classifies the global endoscopy market in terms of four segments, namely, by product, by application, by end user, and by geography. By product, the market is divided into esophageal capsule, small bowel capsule, and colon capsule.
Global Adalimumab Biosimilar Market to Expand with Rising Prevalence of Arthritis, Says Fortune Business Insights
Market Overview
The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it.
The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis. A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
Market Overview
The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it.
The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis. A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
Global Adalimumab Biosimilar Market to Expand with Rising Prevalence of Arthritis, Says Fortune Business Insights
Market Overview
The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it.
The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis. A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
Market Overview
The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it.
The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis. A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
The rising demand for time-efficient artificial intelligence systems for resolving complex medical conditions is driving the “global artificial intelligence in healthcare market” says Fortune business Insights in a report, titled “Artificial Intelligence in Healthcare Market Size, Share And Global Trend By Platform (Hardware, Software, Services), By Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Clinical Trial Participant Identifier, Preliminary Diagnosis), By End User (Hospitals, Clinics, Industries, Healthcare Provider, Pharmaceutical & Biotechnology Company), And Geography Forecast Till 2026”.Growing prevalence of chronic diseases is shifting the focus to artificial intelligence in healthcare
Request a Sample Copy of the Research Report
Request a Sample Copy of the Research Report
The rising demand for time-efficient artificial intelligence systems for resolving complex medical conditions is driving the “global artificial intelligence in healthcare market” says Fortune business Insights in a report, titled “Artificial Intelligence in Healthcare Market Size, Share And Global Trend By Platform (Hardware, Software, Services), By Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Clinical Trial Participant Identifier, Preliminary Diagnosis), By End User (Hospitals, Clinics, Industries, Healthcare Provider, Pharmaceutical & Biotechnology Company), And Geography Forecast Till 2026”.Growing prevalence of chronic diseases is shifting the focus to artificial intelligence in healthcare
Request a Sample Copy of the Research Report
Request a Sample Copy of the Research Report
Artificial Intelligence in Healthcare Market To Witness Considerable Growth; Utilization Of Artificial Intelligence Will Resolve Complex Medical Conditions, Says Fortune Business Insights
Market Overview
The rising demand for time-efficient artificial intelligence systems for resolving complex medical conditions is driving the “global artificial intelligence in healthcare market” says Fortune business Insights in a report, titled “Artificial Intelligence in Healthcare Market Size, Share And Global Trend By Platform (Hardware, Software, Services), By Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Clinical Trial Participant Identifier, Preliminary Diagnosis), By End User (Hospitals, Clinics, Industries, Healthcare Provider, Pharmaceutical & Biotechnology Company), And Geography Forecast Till 2026”.
Request a Sample Copy of the Research Report
Market Overview
The rising demand for time-efficient artificial intelligence systems for resolving complex medical conditions is driving the “global artificial intelligence in healthcare market” says Fortune business Insights in a report, titled “Artificial Intelligence in Healthcare Market Size, Share And Global Trend By Platform (Hardware, Software, Services), By Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Clinical Trial Participant Identifier, Preliminary Diagnosis), By End User (Hospitals, Clinics, Industries, Healthcare Provider, Pharmaceutical & Biotechnology Company), And Geography Forecast Till 2026”.
Request a Sample Copy of the Research Report